November 23, 2021, 10:56 am Israeli oral Covid vaccine to be developed in Mexico Oramed’s Oravax Medical and Genomma Lab Internacional announce joint venture to develop and commercialize vaccine for Latin America. By Abigail Klein Leichman
August 9, 2021, 9:00 am Will an Israeli vaccine be the solution to new variants? Injectable and oral vaccines under development in Israel may prove significant in protecting people from mutations of the SARS-CoV-2 coronavirus. By Abigail Klein Leichman
March 29, 2021, 8:40 am Oral Covid vaccine candidate produces antibodies in pigs Oramed Pharmaceuticals of Jerusalem and Premas Biotech of India form new company to develop revolutionary coronavirus inoculation. By Abigail Klein Leichman
November 9, 2017, 8:30 am 10 advances transforming the lives of diabetics worldwide From an oral insulin capsule to a noninvasive glucose monitor, Israeli entrepreneurs and researchers are making life easier for diabetics. By Abigail Klein Leichman
July 15, 2015, 11:41 am AnyClip Media raises $21 million Jerusalem-based startups AnyClip, Oramed, Qlight record top investments and acquisitions. By Viva Sarah Press
January 13, 2015, 6:00 am Tech firms target diabetes (audio) Listen in to find out more about these made-in-Israel technologies aimed at improving quality of life for people with diabetes. By ISRAEL21c Staff
February 11, 2014, 6:51 am Oramed announces successful oral insulin clinical trials FDA Phase 2a results move Israeli pharmaceutical company one step closer to world's first insulin pill. By Viva Sarah Press
December 22, 2013, 12:30 am Top 10 Israeli medical advances to watch in 2014 ISRAEL21c compiles a list of the 10 most extraordinary medical devices and pharmaceuticals that promise to revolutionize global healthcare. By Abigail Klein Leichman
February 12, 2013, 2:54 am Groundbreaking insulin pill nearing market For 100 years, scientists searched for a way to deliver insulin orally instead of by injection. Now an Israeli team claims it’s found the solution. Phase 2 clinical trials are coming. By Abigail Klein Leichman
